Results 31 to 40 of about 9,921 (221)
Background KRAS^G12C inhibitors (KRAS^G12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRAS^G12C-mutant cancers.
Yafang Wang +9 more
semanticscholar +1 more source
Dual Inhibition of γ-Tubulin and Plk1 Induces Mitotic Cell Death
α/β-Tubulin inhibitors that alter microtubule (MT) dynamics are commonly used in cancer therapy, however, these inhibitors also cause severe side effects such as peripheral neuropathy.
Haruna Ebisu +12 more
doaj +1 more source
Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis [PDF]
Several kinases phosphorylate vimentin, the most common intermediate filament protein, in mitosis. Aurora-B and Rho-kinase regulate vimentin filament separation through the cleavage furrow-specific vimentin phosphorylation.
Erich A. Nigg +19 more
core +1 more source
Ubiquitin‐specific peptidase 24 (USP24), a member of the deubiquitinase family, plays an important role in tumor regulation. However, the role of USP24 in gastric cancer (GC) is unknown. The aim of our study was to explore the role of USP24 in GC to seek
Xiao-Fei Zhi +3 more
semanticscholar +1 more source
Polo-like kinase (Plk1) plays a central role in regulating the cell cycle. Plk1-mediated phosphorylation is essential for centrosome maturation, and for numerous mitotic events.
Tamina Seeger-Nukpezah +6 more
doaj +1 more source
Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy [PDF]
Advanced techniques for detecting kinase inhibitors are in demand due to limitations of traditional approaches. Here, we used a fluorescence resonance energy transfer (FRET)-based kinase assay, a sensitive fluorescence turn-on biosensing platform, to identify a Polo-like kinase 1 (PLK1) inhibitor.
Sol-Bi, Shin +3 more
openaire +2 more sources
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells [PDF]
High attrition rates of novel anti-cancer drugs highlight the need for improved models to predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug development, the role of Plk1 in primary cells remains widely ...
Kappel, Sven +74 more
core +1 more source
Plk1 promotes renal tubulointerstitial fibrosis by targeting autophagy/lysosome axis
The prevalence of chronic kidney disease (CKD) has been increasing over the past decades. However, no effective therapies are available for delaying or curing CKD.
Yang Du +12 more
semanticscholar +1 more source
Tumor inhibition by genomically integrated inducible RNAi-cassettes [PDF]
RNA interference (RNAi) has emerged as a powerful tool to induce loss-of-function phenotypes by post-transcriptional silencing of gene expression. In this study we wondered whether inducible RNAi-cassettes integrated into cellular DNA possess the power ...
Kappel, Sven +8 more
core +1 more source
Targeting Plk1 sensitizes pancreatic cancer to immune checkpoint therapy
Polo-like kinase 1 (Plk1) plays an important role in cell cycle regulation. Recent work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic ductal adenocarcinoma (PDAC).
Zhuangzhuang Zhang +17 more
semanticscholar +1 more source

